Ceftiofur

Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.^[1] It is marketed by pharmaceutical company Pfizer as Excede.^[2]

Additional recommended knowledge

Guide to balance cleaning: 8 simple steps

Recognize and detect the effects of electrostatic charges on your balance

Better weighing performance in 6 easy steps

It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.^[3]

References

1. ^ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). "Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice". Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686.
2. ^ Pfizer Animal ealth Dairy Information on Products and Solutions. Retrieved on 2007-11-20.
3. ^ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). "Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves". Appl. Environ. Microbiol. 72 (6): 3940–8. doi:10.1128/AEM.02770-05. PMID 16751500.